poly (ADP-ribose) in Vietnamese


poly ADP-riboza (loại polynucleotit thứ ba sau ADN và ARN tồn tại trong tế bào của sinh vật có nhân điển hình)

Sentence patterns related to "poly ADP-ribose"

Below are sample sentences containing the word "poly ADP-ribose" from the English - Vietnamese Medical Dictionary. We can refer to these sentence patterns for sentences in case of finding sample sentences with the word "poly ADP-ribose", or refer to the context using the word "poly ADP-ribose" in the English - Vietnamese Medical Dictionary.

1. Furthermore, poly(ADP-ribose) polymerase (PARP) inhibitors could further expand the treatment options for recurrent disease.

2. Poly(adp-ribose) polymerase ('parp') inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage

3. Anti-PARP1 (Cleaved form) Antibody from rabbit, purified by affinity chromatography; Synonym: Poly [ADP-ribose] polymerase 1, PARP-1, NAD(+) ADP-ribosyltransferase 1, ADPRT 1, Poly[ADP-ribose] synthase 1, ARTD1; find Sigma-Aldrich-ABC26 MSDS, related peer-reviewed papers, technical documents, similar products & more at Sigma-Aldrich.

4. Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed.

5. The poly(ADP-ribose) structure is involved in the regulation of several cellular events and is most important in the cell nucleus, in processes such as DNA repair and telomere maintenance.

6. The present invention relates to a pharmaceutical composition for treating chronic myeloid leukemia, containing a Liriodendron tulipifera L. bark extract as an active ingredient, and more specifically, to a pharmaceutical composition for treating chronic myeloid leukemia, containing a Liriodendron tulipifera L. bark extract, which causes cell death by a change in mitochondrial membrane potential (MMP) in leukemia cells, and the cleavage of poly(ADP-ribose) polymerase (PARP) and caspase-3 related to a cell death pathway, in order to selectively inhibit the T315I mutant enzyme generated by the mutation of the BCR-ABL fusion gene, which is a gene causing chronic myeloid leukemia.

7. The present invention relates to a pharmaceutical dosage form for treating chronic myeloid leukemia, containing a Liriodendron tulipifera L. bark extract as an active ingredient, and more specifically, to a pharmaceutical dosage form for treating chronic myeloid leukemia, containing a Liriodendron tulipifera L. bark extract, which causes cell death by a change in mitochondrial membrane potential (MMP) in leukemia cells and the cleavage of poly(ADP-ribose) polymerase (PARP) and caspase-3 related to a cell death pathway, in order to selectively inhibit the T315I mutant enzyme generated by the mutation of the BCR-ABL fusion gene, which is a gene causing chronic myeloid leukemia.